Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)

Clinical and Experimental Rheumatology

Volumn 28, Issue 1, 2010, Pages 141-142

  Yoshimura, M ^a   Makiyama, J ^a   Koga, T ^a   Miyashita, T ^a   Izumi, Y ^a   Torigoshi, T ^a   Motokawa, S ^a   Eguchi, K ^b   Migita, Kiyoshi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB;

ADULT; ADULT ONSET STILL DISEASE; ARTHRALGIA; BODY RASH; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; JOINT RADIOGRAPHY; LETTER; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT DURATION; WRIST;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; MIDDLE AGED; STILL'S DISEASE, ADULT-ONSET; WRIST JOINT;

EID: 77949512903     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. KOKKINOS A, ILIOPOULOS A, GREKA P, EFTHYMIOU A, KATSILAMBROS N, SFIKAKIS PP: Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004; 23: 45-9.
2. FAUTREL B, SIBILIA J, MARIETTE X, COMBE B: Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64: 262-6.
3. NISHIMOTO N, TERAO K, MIMA T, NAKAHARA H, TAKAGI N, KAKEHI T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.
4. IWAMOTO M, NARA H, HIRATA D, MINOTA S, NISHIMOTO N, YOSHIZAKI K: Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46: 3388-9.
5. NAKAHARA H, MIMA T, YOSHIO-HOSHINO N, MATSUSHITA M, HASHIMOTO J, NISHIMOTO N: A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 2009; 19: 69-72.
6. DE BANDT M, SAINT-MARCOUX B: Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 2009; 68: 153-4.
7. NISHIMOTO N, HASHIMOTO J, MIYASAKA N et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
8. YOSHIZAKI A, KAWAKAMI A, ARAMAKI T, IDA H, EGUCHI K: Preferential recovery by an intensive initial therapy from hemophagocytic syndrome complicated with adult onset Still's disease presenting as agranulocytosis and hypercytokinemia. Clin Exp Rheumatol 2008; 26: 383.
9. MATSUMOTO K, NAGASHIMA T, TAKATORI S et al.: Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 2009; 28: 485-7.
10. FITZGERALD AA, LECLERCQ SA, YAN A, HOMIK JE, DINARELLO CA: Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52: 1794-803.
11. LEQUERRÉ T, QUARTIER P, ROSELLINI D et al.: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
12. PRIORI R, CECCARELLI F, BARONE F, IAGNOCCO A, VALESINI G: Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease. Clin Exp Rheumatol 2008; 26: 933-7.
13. GUIGNARD S, DIEN G, DOUGADOS M: Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007; 25: 758-9.